TuHURA Biosciences reported a net loss of $23.2 million for the nine months ended September 30, 2026, compared to a $23.3 million loss in the prior year. The company significantly increased its total assets to $36.2 million, primarily through the capitalization of $6.9 million in revolving credit facility debt issuance costs and $2.9 million in prepaid R&D expenses.
TuHURA Biosciences reported financial results for the third quarter ended September 30, 2026, and provided updates on its Phase 3 immuno-oncology programs. The company highlighted positive preliminary data from its IFx-2.0 study in Merkel cell carcinoma and received FDA clearance to begin a Phase 1b study for its VISTA-inhibiting antibody, TBS-2025. Management noted that operations remain funded through a $50 million credit facility from its largest shareholder.
Term
Q3 2026
“We continue to make significant progress across each of our programs. In October, we shared our first look at data from our open-label front line study of IFx-2.0 with Keytruda® in patients with deep-seated metastatic Merkel cell carcinoma, which showed durable, major objective anti-tumor responses in the first three patients with all responses ongoing for more than six months.”
Dr. James Bianco, President and Chief Executive Officer
“With meaningful progress having been made in each of our programs, we believe we are well positioned to deliver on several transformational potential milestones. Having continuing access to a $50mm credit facility from our largest shareholder has allowed us to fund operations in a non-dilutive manner benefiting shareholders as we continue driving towards these value-creating events.”
Dr. James Bianco, President and Chief Executive Officer
TuHURA Biosciences $50M Debt Financing with Parkview Holdings One LLC
TuHURA Biosciences borrowed an additional $1.5 million under its existing revolving credit facility with Parkview Holdings One LLC. The facility, which matures in April 2031, has a maximum loan availability of $50 million. The company intends to use the proceeds for general corporate purposes.
TuHURA Biosciences $50M Debt Financing with Parkview Holdings One LLC
TuHURA Biosciences received and borrowed an additional $650,000 draw under its existing $50 million revolving credit facility with Parkview Holdings One LLC. The facility matures on April 21, 2031, and the company intends to use the proceeds for general corporate purposes.
TuHURA Biosciences $650K Debt Financing with Parkview Holdings One LLC
TuHURA Biosciences borrowed an additional $650,000 under its existing $50 million revolving credit facility with Parkview Holdings One LLC. The funds are intended for general corporate purposes, and the underlying loan agreement matures on April 21, 2031.
TuHURA Biosciences $650K Debt Financing with Parkview Holdings One LLC
TuHURA Biosciences drew down an additional $650,000 from its existing $50 million revolving credit facility with Parkview Holdings One LLC. The funds are intended for general corporate purposes, and the underlying loan agreement matures in April 2031.